Interestingly, mutations of the EGF receptor (EGFR) have been associated with several types of cancers, including lung cancer, and targeted therapy using small molecules disrupting kinase activity of EGFR results in considerable clinical benefit in lung cancer patients [4]. The gene discussed is EGFR; the disease is cancer.